About this paper
Pressured by new regulations, public image issues, negative publicity and a desire to promote better use of health data, pharmaceutical companies and other clinical trial sponsors are starting initiatives to expose and share their clinical trial information. Recent announcements to share previously confidential data include those by GlaxoSmithKline and the CEO Roundtable on Cancer. In addition to positive media attention and altruistic reasons, pharmaceutical companies also see this as an opportunity to improve the research process and increase the opportunities to identify scientific breakthroughs helping both their companies as well as the larger healthcare environment. Providing access to clinical trial data with the ability to aggregate information for meta-analyses greatly increases the likelihood for identifying new medical breakthroughs as well as decreasing the time to market for
SAS is the leader in business analytics software and services, and the largest independent vendor in the business intelligence market. Through innovative solutions, SAS helps customers at more than 70,000 sites improve performance and deliver value by making better decisions faster. Since 1976 SAS has been giving customers around the world THE POWER TO KNOW® .
Have a SAS profile? To complete this form automatically: Login